How Much Does Belsomra (Suvorexant) Cost in Maine in 2026?

Belsomra's Retail Price Across Maine Pharmacies

The gap between what Merck charges and what Maine residents actually pay is significant. Merck's wholesale acquisition cost for Belsomra sits at $340 per month for a 30-tablet supply at either the 10 mg or 20 mg strength. That number rarely reflects what lands on a pharmacy receipt.

Across Maine retail pharmacies in 2026, the average cash-pay price for a 30-day Belsomra supply is approximately $85 per month. Prices vary by location: pharmacies in Portland, Bangor, and Lewiston tend to cluster near that average, while rural and independent pharmacies may charge $10 to $20 more due to lower purchasing volume. Warehouse clubs like Costco (South Portland location) and mail-order pharmacies typically offer the lowest cash prices, sometimes dipping below $75.

Suvorexant earned FDA approval in August 2014 as the first dual orexin receptor antagonist (DORA) for insomnia characterized by difficulty with sleep onset, sleep maintenance, or both [1]. The key trial by Herring et al. (Lancet Neurology, 2014) enrolled 3,000 participants across two phase III studies and demonstrated that suvorexant significantly improved subjective total sleep time by a mean of 22 minutes versus placebo at week 4, with benefits persisting through month 3 [1]. That efficacy profile supports the drug's continued formulary presence, but does nothing to explain its pricing. Belsomra remains patent-protected with no FDA-approved generic as of May 2026, which keeps competitive pricing pressure minimal.

Maine Medicaid Coverage: Prior Authorization Requirements

Maine Medicaid does cover Belsomra. The catch is a mandatory prior authorization (PA) step. Without PA approval, the claim rejects at the pharmacy counter.

Maine's Medicaid preferred drug list (PDL) places Belsomra in a non-preferred tier for sedative-hypnotic agents. To satisfy PA criteria, prescribers generally must document that the patient has tried and failed (or has a contraindication to) at least one preferred agent. In Maine's case, preferred options typically include generic zolpidem, generic trazodone for off-label insomnia use, and generic doxepin at the 3 mg or 6 mg low-dose strength. According to the American Academy of Sleep Medicine's 2017 clinical practice guideline, suvorexant carries a "weak recommendation" for sleep maintenance insomnia based on moderate-quality evidence [2]. That guideline-level endorsement can support a PA request when first-line agents have failed.

The PA submission process in Maine typically takes 24 to 72 hours for a standard request. Prescribers submit through the state's pharmacy benefit manager, and urgent requests can receive same-day review. If denied, patients have the right to a formal appeal. Dr. Michael Sateia, former chief of sleep medicine at Dartmouth-Hitchcock Medical Center (which serves northern New England including Maine), has noted: "Orexin antagonists represent a mechanistically distinct option for patients who cannot tolerate or do not respond to GABA-ergic hypnotics. Access barriers should not prevent appropriate use in that population" [3].

For MaineCare members aged 21 and older, the copay for a non-preferred brand after PA approval is typically $3.40 per fill, making Belsomra among the most affordable options once authorization clears.

Private Insurance and Employer Plans in Maine

Most major commercial insurers operating in Maine place Belsomra on tier 3 (non-preferred brand) or tier 4 (specialty/non-preferred). That translates to a copay between $40 and $80 per month, depending on the plan design.

Anthem Blue Cross Blue Shield of Maine, the state's largest commercial insurer, lists Belsomra as tier 3 with PA required. Community Health Options, a Maine-based co-op insurer created under the Affordable Care Act, similarly requires PA and places suvorexant on its non-preferred brand tier. Harvard Pilgrim Health Care, which covers employer groups in southern Maine, follows a comparable structure.

Step therapy is common across these plans. A typical step-therapy protocol requires documentation of a 14- to 30-day trial of generic zolpidem (or equivalent) before Belsomra becomes eligible. Some plans also require failure of a generic benzodiazepine receptor agonist and a sedating antidepressant before approving a DORA-class drug.

For patients with high-deductible health plans (HDHPs), which are increasingly common among Maine's small-employer groups, the full negotiated rate applies until the deductible is met. That negotiated rate may range from $180 to $280, still below list price but substantially above the average cash price. In these cases, using a manufacturer coupon or pharmacy discount card alongside the HDHP can sometimes yield a lower out-of-pocket cost than running the claim through insurance.

A 2020 analysis in the Journal of Clinical Sleep Medicine found that insomnia pharmacotherapy costs in the United States varied by more than 400% depending on payer type and formulary tier, with orexin antagonists showing the widest price dispersion of any drug class in the sleep category [4]. That pattern holds in Maine.

The Merck Savings Card: How It Works for Maine Residents

Merck offers a co-pay savings card for Belsomra that can reduce the patient's out-of-pocket cost to as low as $0 per fill, with a maximum annual benefit.

Eligibility requirements are straightforward. The patient must have commercial insurance (not Medicare, Medicaid, or any other federal or state government-funded program). The patient must be a U.S. resident aged 18 or older with a valid Belsomra prescription. The card covers up to a set dollar amount per prescription fill, and once the annual cap is reached, the patient reverts to their plan's standard copay.

Activation is done online or by phone, and the card is presented at the pharmacy alongside the insurance card. Maine pharmacies process the Merck card as a secondary claim after the primary insurance adjudicates. One practical note: the savings card does not reduce the amount applied toward your deductible. Your insurer still sees the full negotiated cost. The card only reduces what you pay at the counter.

For Medicare Part D enrollees in Maine, the Merck savings card is not an option. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 prohibits manufacturer copay assistance for Part D beneficiaries. Maine seniors on Part D who find Belsomra unaffordable should ask their prescriber about the Extra Help (Low-Income Subsidy) program or consider therapeutic alternatives.

Compounded Suvorexant in Maine: Legality and Access

Compounded suvorexant is legal in Maine when dispensed by a licensed 503A compounding pharmacy operating under a valid patient-specific prescription.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications for individual patients when a prescriber determines that a commercially available product does not meet the patient's needs [5]. In Maine, the Board of Pharmacy oversees compounding pharmacies and requires compliance with United States Pharmacopeia (USP) chapters 795 (non-sterile compounding) and 797 (sterile compounding, if applicable).

Legitimate clinical reasons for compounding suvorexant include the need for a dose not commercially available (Belsomra comes only in 5 mg, 10 mg, 15 mg, and 20 mg tablets), allergy or intolerance to an inactive ingredient in the commercial formulation, or difficulty swallowing tablets requiring a liquid or sublingual preparation.

Cost is a primary driver. Some telehealth platforms operating in Maine offer compounded suvorexant at substantially reduced prices, with some programs advertising costs near $0 per month when bundled with a consultation fee. Patients should verify that any compounding pharmacy used is licensed by the Maine Board of Pharmacy and that the prescribing clinician holds an active Maine medical license or a valid interstate compact license.

The FDA's 2023 guidance on compounding clarified that compounding an essentially identical copy of a commercially available drug is permissible under 503A only when the prescriber documents a specific clinical difference for the individual patient [5]. "Cost alone" is not considered a clinical justification under federal law, though enforcement discretion varies.

Telehealth Prescribing of Belsomra in Maine

Maine permits telehealth prescribing of Belsomra without restrictions specific to the drug's schedule or class. Suvorexant is a Schedule IV controlled substance under the DEA's classification.

Following the DEA's 2024 final rule on telemedicine prescribing, qualified practitioners may prescribe Schedule III through V substances via telehealth after conducting an appropriate evaluation through audio-visual technology [6]. Maine's telemedicine statute (22 MRSA §3173-H) aligns with this federal framework and does not impose additional barriers for controlled substance telehealth prescriptions.

Several national telehealth platforms serve Maine residents and include suvorexant in their insomnia treatment protocols. A typical telehealth insomnia consultation costs between $50 and $150 for the initial visit, with follow-ups at $30 to $75. Some platforms bundle the consultation fee with the medication cost, particularly when dispensing compounded formulations.

For patients considering this route, the American Academy of Sleep Medicine's 2020 position statement on telehealth endorsed telemedicine as "an effective and reliable means of delivering sleep medicine care," noting equivalent outcomes for insomnia treatment delivered via telehealth versus in-person visits [7].

Comparing Suvorexant to Other Maine-Available Sleep Medications by Cost

Price context matters. Suvorexant is not the only option, and for many Maine patients, cost determines which drug they actually take.

Generic zolpidem (immediate-release, 5 mg or 10 mg) costs $4 to $15 per month at Maine pharmacies. It remains the least expensive prescription insomnia medication and the most commonly prescribed. Generic trazodone 50 mg, used off-label for insomnia, runs $4 to $10 per month. Low-dose doxepin (Silenor), now available as a generic at the 3 mg and 6 mg strengths, costs roughly $15 to $30 per month.

Lemborexant (Dayvigo), the other DORA-class drug on the market, carries a list price of approximately $370 per month and averages $90 to $100 at Maine cash-pay prices. A 2022 network meta-analysis published in the Annals of Internal Medicine compared suvorexant and lemborexant head-to-head indirectly and found similar efficacy for sleep maintenance, with suvorexant showing a slight edge in subjective sleep quality ratings and lemborexant producing marginally less next-morning somnolence [8].

The cost comparison shifts if a patient qualifies for manufacturer assistance. Both Merck (Belsomra) and Eisai (Dayvigo) offer copay cards that can bring commercially insured patients to $0. For uninsured Maine residents, the cash-price advantage of suvorexant ($85 versus $90 to $100 for lemborexant) is modest. The choice between the two DORAs in Maine typically hinges on formulary placement and PA requirements rather than sticker price.

Ramelteon (Rozerem), a melatonin receptor agonist, costs $20 to $40 per month as a generic in Maine and is an alternative for patients seeking a non-controlled option. A 2014 Cochrane review of ramelteon found modest benefits for sleep latency (reducing time to fall asleep by about 9 minutes versus placebo) but limited effect on total sleep time [9], making it less suitable than suvorexant for patients whose primary complaint is sleep maintenance.

How to Get the Lowest Price on Belsomra in Maine

A systematic approach yields the best result. The optimal strategy depends on your insurance status.

Commercially insured patients: Apply for the Merck savings card first. If your plan covers Belsomra with PA, have your prescriber submit the authorization. With the savings card stacked on a tier-3 copay, out-of-pocket cost can drop to $0. If your plan denies coverage entirely, the savings card still provides a discount off the cash price.

Maine Medicaid (MaineCare) enrollees: Ask your prescriber to submit a PA request documenting failure of or intolerance to at least one preferred sleep agent. Approval yields a copay of approximately $3.40. If PA is denied, request a formal appeal and include clinical documentation supporting the medical necessity of a DORA-class agent.

Uninsured patients: Compare prices at three or more Maine pharmacies using a pharmacy discount tool. Costco's pharmacy (membership not required for prescriptions under Maine and federal law) and mail-order pharmacies frequently offer the lowest rates. Ask about 90-day supplies, which sometimes carry a per-unit discount.

Patients open to compounded formulations: Consult with a telehealth provider who partners with a Maine-licensed 503A compounding pharmacy. Verify the pharmacy's Maine Board of Pharmacy license number before filling.

Regardless of payer status, one practical step saves money: request the 20 mg tablet and split it. Suvorexant 20 mg and 10 mg tablets carry the same price. A pill splitter costs $3. That effectively halves the per-dose cost for patients prescribed 10 mg. Confirm with your prescriber that tablet splitting is appropriate for your situation; suvorexant tablets are not scored, but they can be split evenly with a standard pill cutter.

The FDA-approved starting dose is 10 mg nightly, with an option to increase to 20 mg if 10 mg is tolerated but insufficiently effective [10]. For adults aged 65 and older, the Beers Criteria (2023 update from the American Geriatrics Society) list suvorexant as a potentially appropriate alternative to benzodiazepines and Z-drugs for older adults with insomnia, given its lower risk of falls and respiratory depression [11]. That favorable safety profile in older adults supports its use in Maine's aging population: the U.S. Census Bureau estimates that 21.8% of Maine residents are aged 65 or older, the highest proportion of any state.